We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NVMI:TASENova Ltd. Analysis

Data as of 2026-05-22 - not real-time

$496.50

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

The stock is trading at $496.5, comfortably above the computed support level of $462.77 yet still 12% below the identified resistance of $565, indicating room for upside if momentum sustains.
Technical gauges show a bullish trend direction with volume accelerating, but the MACD bearish signal and a neutral RSI of 48.9 temper short‑term optimism.
Fundamentally, Nova Ltd. delivers robust profitability—gross margin of 57.3%, operating margin of 30.1% and profit margin of 29.2%—and a 10.3% revenue growth rate, underscoring strong operating performance.
However, valuation metrics flag concerns: a trailing PE of 62.1 far exceeds the industry average of 39.1, a price‑to‑book of 12×, and a debt‑to‑equity of 57.7×, all of which inflate systematic and financial risk.
Risk indicators are pronounced: beta of 2.6 and 30‑day volatility near 61% suggest heightened market sensitivity, while a max drawdown of –21.6% reflects downside vulnerability.
Given this mix of bullish price action, solid earnings, but elevated valuation and leverage, the short‑term stance leans toward hold pending clearer momentum, the medium‑term view favors a buy on fundamentals, and the long‑term outlook recommends a cautious hold pending valuation compression.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price above support but below resistance
  • neutral RSI and bearish MACD
  • increasing volume indicating momentum

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • strong margin profile and revenue growth
  • forward PE still high but improving
  • robust operating cash flow

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • significant overvaluation relative to industry
  • high leverage and beta increasing systematic risk
  • potential for valuation compression as market normalises

Key Metrics & Analysis

Financial Health

Revenue Growth10.30%
Profit Margin29.21%
P/E Ratio62.1
ROE22.25%
ROA8.40%
Debt/Equity57.67
P/B Ratio12.0
Op. Cash Flow$217.1M
Free Cash Flow$122.4M
Industry P/E39.1

Technical Analysis

TrendBullish
RSI48.9
Support$462.77
Resistance$565.00
MA 20$508.73
MA 50$488.22
MA 200$381.74
MACDBearish
VolumeIncreasing
Fear & Greed Index91.5

Valuation

Fair Value$86.70
Target Price$597.63
Upside/Downside20.37%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.63
Volatility60.96%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.